Ocular / Choroidal Melanoma
Conditions
Interventions
Treatment period of 4 to 6 days. Initial dose to be 64Gy(RBE) in 4 fractions. After 5 cases, dose to be escalated to 68Gy(RBE) in 4 fractions.
Sponsors
National Institutes for Quantum and Radiological Science and Technology National Institute of Radiological Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed ocular / choroidal melanoma. 2. Size of the tumor can be evaluated. 3. Performance Status (ECOG) is between 0-2 4. Any patient who posses ability to consent. Patients below 20 y.o must possess the ability to fully comprehend their disease and treatment options and assent to participate in this study on written matter alongside with consent of the guardian(s).
Exclusion criteria
Exclusion criteria: 1. Existence of past treatment against the lesion. 2. Existence of extra-ocular lesion including metastasis. 3. Life expectancy shorter than 6 months 4. Active infection within the irradiation field 5. Existence of other active malignancies. 6. Existence of severe complications 7. Evaluated not able to complete this study because of serious medical or psychological problems
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Normal tissue acute toxicity. (to be evaluated at end of treatment, 3 months and 6 months post-treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Initial response Local control rate Normal tissue late toxicity Overall survival rate Eye retention rate | — |
Countries
Japan
Contacts
Public ContactHiroshi Tsuji
National Institutes for Quantum and Radiological Science and Technology National Institute of Radiological Sciences Hospital
Outcome results
None listed